Tazemetostat: Phase II started

Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The

Read the full 223 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE